Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

GeNeuro Phase IIb Launch And Partner's Equity Investment

This article was originally published in Scrip

Executive Summary

GeNeuro SA. has begun its proof-of-concept Phase IIb study, CHANGE-MS, with lead product GNbAC1, an antibody targeting the protein MSRV-Env expressed in multiple sclerosis (MS). Servier, the company's development partner, has also exercised its equity investment option to become a minority shareholder in GeNeuro by buying shares from existing shareholder Eclosion2.